Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Clin Cancer Res · 2026 · PMC13056312 · PMID 41385615

Europe PMC DOI

hedged sentence

0.5200

closest p · 10.4× alpha

0.5200

boldest claim

The sentences

showed a trendP = 0.52not close (p > 0.1)

Tumors with Ki-67 ≥30% and/or RS results ≥26 showed a trend toward higher RCB 0 to I rates with chemotherapy (23% vs. 17%; P = 0.52).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.